EGF and prostate carcinoma: Figure 2D shows that treatment of DU-145 or PC3 cells with MIG6 siRNA but not with control siRNA resulted in increased response to EGF, which shows that the MIG6 protein functions as a negative regulator of EGFR signaling in prostate cancer derived cells.